Welcome to our dedicated page for CME Group SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CME Group Inc. (CME) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a publicly traded operator in the securities and commodity exchanges industry. CME Group files a range of documents with the U.S. Securities and Exchange Commission, including current reports on Form 8-K that provide updates on financial results, corporate events and governance matters.
Recent Form 8-K filings illustrate how CME Group uses SEC reports to communicate with investors. One 8-K describes the release of quarterly financial results, including the use of non-GAAP measures such as non-GAAP revenues, expenses, operating income, net income and earnings per share, together with reconciliations to the most comparable GAAP figures. Another 8-K reports a jury verdict in favor of CME Group and the Board of Trade of the City of Chicago, Inc. in a class action involving certain Class B shareholders and members. A further 8-K discloses the planned retirement of the company’s Chief Accounting Officer and outlines the transition process.
In addition to 8-Ks, CME Group’s SEC reporting framework includes annual and quarterly reports, proxy statements and other filings that address topics such as results of operations, financial condition, risk factors, corporate governance and compensation. These documents help investors understand the company’s role as a derivatives marketplace offering futures, options, cash and OTC trading across interest rates, equity indexes, foreign exchange, energy, agricultural products, metals and cryptocurrencies, as well as its operation of CME Clearing and electronic platforms like CME Globex, BrokerTec and EBS.
On Stock Titan, CME filings are supplemented with AI-powered summaries designed to explain the key points of lengthy documents, such as 10-K and 10-Q reports, in accessible language. Users can quickly identify major themes, while still having access to the full text of each filing. The page also provides visibility into event-driven filings like Form 8-K, which can include announcements about earnings releases, legal outcomes, executive changes and other material developments.
CME Group Inc. senior managing director and general counsel Jonathan L. Marcus received an equity award of 5,270 shares of Class A common stock on March 15, 2026. The vesting amount was based on CME’s total shareholder return versus the S&P 500 over a three-year period from January 1, 2023 through December 31, 2025.
On the same date, Marcus surrendered 2,377 shares to the company to cover tax withholding on the performance share award and 261 shares to cover taxes on restricted stock vesting. These tax-withholding dispositions were not open-market sales. After these transactions, he directly holds 10,483 CME Class A shares.
CME Group Sr MD & Chief HR Officer Hilda Harris Piell reported compensation-related share activity. She received 7,076 shares of Class A common stock as a grant tied to performance shares awarded in 2022 under CME Group's Omnibus Stock Plan, based on total shareholder return relative to the S&P 500 over a three-year period ending December 31, 2025. To cover tax withholding on this award, she surrendered 3,039 shares back to the company. After these transactions, she directly holds 33,455 shares of CME Group Class A common stock.
CME Group COO & Global Head of Clearing Suzanne Sprague received 5,504 shares of Class A common stock as a performance share award. The vested shares were granted under CME Group's Omnibus Stock Plan and were based on the company's total shareholder return versus the S&P 500 over a three-year period ending December 31, 2025.
To cover tax withholding obligations tied to this vesting and to separate restricted stock vesting on March 15, 2026, she surrendered a total of 2,515 shares back to the company. After these compensation-related and tax-withholding entries, she directly holds 13,836 shares of CME Group Class A common stock.
CME Group Chairman and CEO Terrence A. Duffy reported the vesting of 62,902 shares of Class A common stock on March 15, 2026. These performance shares were granted in 2022 and vested based on CME Group’s total shareholder return versus the S&P 500 over the period from January 1, 2023 through December 31, 2025.
To cover related tax withholding obligations, Duffy surrendered 27,866 shares back to the company at a reference price of $311.40 per share. After these compensation-related transactions, he directly holds 90,630 shares of CME Group Class A common stock, reflecting a routine equity award and associated tax withholding rather than open-market buying or selling.
CME Group Inc. Chief Transformation Officer Ken Vroman reported routine equity compensation activity. He acquired 7,076 shares of Class A common stock valued at $311.40 per share through the vesting of performance shares granted in 2022 under CME Group's Omnibus Stock Plan.
On the same date, 3,135 shares at $311.40 per share were surrendered back to the company to cover tax withholding obligations related to this award, rather than sold on the open market. Following these transactions, Vroman directly holds 18,851 shares of CME Group Class A common stock.
CME Group Inc. senior managing director and Chief Commercial Officer Julie Winkler reported compensation-related share activity. She acquired 8,256 shares of Class A common stock at $311.40 per share through the vesting of performance shares granted in 2022, based on total shareholder return versus the S&P 500 over a three-year period ending December 31, 2025. To cover tax withholding obligations from this award, she surrendered 3,658 shares back to the company, resulting in a net increase of 4,598 shares and direct ownership of 30,110 shares after the transactions.
CME Group senior executive Derek Sammann received a stock award and surrendered shares for taxes. On March 15, 2026, he acquired 8,256 shares of Class A common stock at $311.40 per share from the vesting of performance shares granted in 2022 under CME Group's Omnibus Stock Plan.
The number of vested shares was based on total shareholder return versus the S&P 500 from January 1, 2023 through December 31, 2025. On the same date, 3,627 shares at $311.40 were surrendered back to the company to cover tax withholding, leaving 13,312 shares held directly. The filing also shows 11,028 shares held indirectly by a trust and 7,022 shares held indirectly by a spouse.
CME Group Inc. President and CFO Lynne Fitzpatrick reported equity compensation activity in the form of vested stock awards. She acquired 5,504 shares of Class A common stock valued at $311.40 per share from performance shares granted in 2022 and earned based on total shareholder return versus the S&P 500 over a three-year period ending December 31, 2025.
Fitzpatrick then surrendered 2,439 shares to the company to satisfy tax withholding obligations on this performance share award and another 76 shares to cover taxes on restricted stock vesting on March 15, 2026. These tax-withholding dispositions were not open-market sales. After these transactions, she directly owned 23,913 shares of CME Group Class A common stock.
CME Group Inc. reported that MD and Chief Accounting Officer Jack J. Tobin received a grant of 608 shares of Class A common stock as a vested performance share award, valued at $311.40 per share. The award reflects performance shares granted in 2022, determined by CME’s total shareholder return versus the S&P 500 over a three-year period from January 1, 2023 through December 31, 2025. To cover related tax withholding obligations, Tobin surrendered 179 shares back to the company. After these compensation-related transactions, he directly holds 25,409 Class A shares.
CME Group Inc. Chief Information Officer Sunil Cutinho reported routine equity compensation activity. On March 15, 2026, 8,256 shares of Class A common stock vested from a performance share award granted in 2022 under CME Group’s Omnibus Stock Plan at a reference price of $311.40 per share.
The vesting was based on the company’s total shareholder return relative to the S&P 500 over a three-year period from January 1, 2023 through December 31, 2025. To satisfy tax withholding obligations related to the award, 3,658 shares were surrendered back to the company at the same price, leaving Cutinho with 23,586 directly held shares after these transactions.